Pharma BD Deal Intelligence
Celgene / Agios (expanded collaboration): Achieved Stated Rationale (Score: 85/100)
Full analysis, sources & comparables →Agios and Celgene cancer metabolism agreement extended with additional $20 million as collaboration yields promising IDH inhibitor candidates
As part of the deal, Celgene will pay Agios $200 million upfront in cash, with various milestone payments possible. For the metabolic immuno-oncology programs,…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Celgene and Agios entered a three-year global strategic collaboration to discover and develop therapies targeting cancer cell metabolism, including IDH1 and IDH2 mutant inhibitors. Agios received $130 million upfront (including an equity investment). Celgene gained exclusive options to license clinical candidates emerging from the collaboration after Phase I. Each optioned program carried up to $120 million in milestones plus royalties. This deal ultimately led to the development of ivosidenib (Tibsovo/IDH1 inhibitor) and enasidenib (Idhifa/IDH2 inhibitor). Rights were later restructured: Celgene retained worldwide enasidenib rights; Agios regained US ivosidenib rights in 2016 amendments, with Celgene keeping ex-US option.
Celgene / Agios (expanded collaboration): Achieved Stated Rationale (Score: 85/100)
Assessment window: 5yr post-close.
Note: this deal's 5-year assessment window closes Apr 2015; the outcome grade above is a projected assessment, not yet finalized.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Agios Pharmaceuticals Inc. (this deal) | 2010 | $130M | 83 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2018 | $9.0B | 68 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Impact Biomedicines | 2018 | $7.0B | 54 |
| Celgene Corporation / Gloucester Pharmaceuticals, Inc. | 2009 | $640M | 40 |
← Browse all deals · How we score deals
More: 2010 deals · Celgene Corporation deals · Oncology deals